Genetic association analyses of PDYN polymorphisms with heroin and cocaine addiction

Genes, Brain and Behavior

Volumn 11, Issue 4, 2012, Pages 415-423

  Clarke, T K ^a   Ambrose Lanci, L ^a   Ferraro, T N ^a   Berrettini, W H ^a   Kampman, K M ^a   Dackis, C A ^a   Pettinati, H M ^a   O'Brien, C P ^a   Oslin, D W ^a,b   Lohoff, F W ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Addiction; Cocaine; Gender; Genetics; Opioids; PDYN

Indexed keywords

PRODYNORPHIN;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; COCAINE DEPENDENCE; CONTROLLED STUDY; EUROPEAN AMERICAN; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEROIN DEPENDENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; AFRICAN AMERICANS; ALLELES; BEHAVIOR, ADDICTIVE; COCAINE-RELATED DISORDERS; ENKEPHALINS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEROIN DEPENDENCE; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN PRECURSORS; SEX FACTORS;

ANIMALIA;

EID: 84862011484     PISSN: 16011848     EISSN: 1601183X     Source Type: Journal    
DOI: 10.1111/j.1601-183X.2012.00785.x     Document Type: Article

References (50)

1. Babbitt, C.C., Silverman, J.S., Haygood, R., Reininga, J.M., Rockman, M.V. & Wray, G.A. (2010) Multiple functional variants in cis modulate PDYN expression. Mol Biol Evol 27, 465-479.
2. Barrett, J.C., Fry, B., Maller, J. & Daly, M.J. (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21, 263-265.
3. Blednov, Y.A., Walker, D., Martinez, M. & Harris, R.A. (2006) Reduced alcohol consumption in mice lacking preprodynorphin. Alcohol 40, 73-86.
4. Buckland, P.R. (2001) Genetic association studies of alcoholism - problems with the candidate gene approach. Alcohol Alcohol 36, 99-103.
5. Chakrabarti, S., Liu, N.J. & Gintzler, A.R. (2010) Formation of mu-/kappa-opioid receptor heterodimer is sex-dependent and mediates female-specific opioid analgesia. Proc Natl Acad Sci U S A 107, 20115-20119.
6. Chen, A.C., LaForge, K.S., Ho, A., McHugh, P.F., Kellogg, S., Bell, K., Schluger, R.P., Leal, S.M. & Kreek, M.J. (2002) Potentially functional polymorphism in the promoter region of prodynorphin gene may be associated with protection against cocaine dependence or abuse. Am J Med Genet 114, 429-435.
7. Clarke, T.K., Krause, K., Li, T. & Schumann, G. (2009) An association of prodynorphin polymorphisms and opioid dependence in females in a Chinese population. Addict Biol 14, 366-370.
8. Dahl, J.P., Weller, A.E., Kampman, K.M., Oslin, D.W., Lohoff, F.W., Ferraro, T.N., O'Brien, C.P. & Berrettini, W.H. (2005) Confirmation of the association between a polymorphism in the promoter region of the prodynorphin gene and cocaine dependence. Am J Med Genet B Neuropsychiatr Genet 139B, 106-108.
9. Di Chiara, G. & Imperato, A. (1988) Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharmacol Exp Ther 244, 1067-1080.
10. Flory, J.D., Pytte, C.L., Hurd, Y., Ferrell, R.E. & Manuck, S.B. (2011) Alcohol dependence, disinhibited behavior and variation in the prodynorphin gene. Biol Psychol 88, 51-56.
11. Frankel, P.S., Alburges, M.E., Bush, L., Hanson, G.R. & Kish, S.J. (2008) Striatal and ventral pallidum dynorphin concentrations are markedly increased in human chronic cocaine users. Neuropharmacology 55, 41-46.
12. Gabriel, S.B., Schaffner, S.F., Nguyen, H., Moore, J.M., Roy, J., Blumenstiel, B., Higgins, J., DeFelice, M., Lochner, A., Faggart, M., Liu-Cordero, S.N., Rotimi, C., Adeyemo, A., Cooper, R., Ward, R., Lander, E.S., Daly, M.J. & Altshuler, D. (2002) The structure of haplotype blocks in the human genome. Science 296, 2225-2229.
13. Gear, R.W., Gordon, N.C., Heller, P.H., Paul, S., Miaskowski, C. & Levine, J.D. (1996a) Gender difference in analgesic response to the kappa-opioid pentazocine. Neurosci Lett 205, 207-209.
14. Gear, R.W., Miaskowski, C., Gordon, N.C., Paul, S.M., Heller, P.H. & Levine, J.D. (1996b) Kappa-opioids produce significantly greater analgesia in women than in men. Nat Med 2, 1248-1250.
15. Gerra, G., Fantoma, A. & Zaimovic, A. (2006) Naltrexone and buprenorphine combination in the treatment of opioid dependence. J Psychopharmacol 20, 806-814.
16. Hurd, Y.L. & Herkenham, M. (1995) The human neostriatum shows compartmentalization of neuropeptide gene expression in dorsal and ventral regions: an in situ hybridization histochemical analysis. Neuroscience 64, 571-586.
17. Kendler, K.S., Jacobson, K.C., Prescott, C.A. & Neale, M.C. (2003) Specificity of genetic and environmental risk factors for use and abuse/dependence of cannabis, cocaine, hallucinogens, sedatives, stimulants, and opiates in male twins. Am J Psychiatry 160, 687-695.
18. Koob, G.F. & Le Moal, M. (2008) Addiction and the brain antireward system. Annu Rev Psychol 59, 29-53.
19. Kreek, M.J., Bart, G., Lilly, C., LaForge, K.S. & Nielsen, D.A. (2005) Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol Rev 57, 1-26.
20. Levran, O., Londono, D., O'Hara, K., Nielsen, D.A., Peles, E., Rotrosen, J., Casadonte, P., Linzy, S., Randesi, M., Ott, J., Adelson, M. & Kreek, M.J. (2008) Genetic susceptibility to heroin addiction: a candidate gene association study. Genes Brain Behav 7, 720-729.
21. Levran, O., Londono, D., O'Hara, K., Randesi, M., Rotrosen, J., Casadonte, P., Linzy, S., Ott, J., Adelson, M. & Kreek, M.J. (2009) Heroin addiction in African Americans: a hypothesis-driven association study. Genes Brain Behav 8, 531-540.
22. Liu, N.J., Chakrabarti, S., Schnell, S., Wessendorf, M. & Gintzler, A.R. (2011) Spinal synthesis of estrogen and concomitant signaling by membrane estrogen receptors regulate spinal {kappa}- and {micro}-opioid receptor heterodimerization and female-specific spinal morphine antinociception. J Neurosci 31, 11836-11845.
23. Mucha, R.F. & Herz, A. (1986) Preference conditioning produced by opioid active and inactive isomers of levorphanol and morphine in rat. Life Sci 38, 241-249.
24. Nestler, E.J. (2004) Historical review: molecular and cellular mechanisms of opiate and cocaine addiction. Trends Pharmacol Sci 25, 210-218.
25. Nikoshkov, A., Drakenberg, K., Wang, X., Horvath, M.C., Keller, E. & Hurd, Y.L. (2008) Opioid neuropeptide genotypes in relation to heroin abuse: dopamine tone contributes to reversed mesolimbic proenkephalin expression. Proc Natl Acad Sci U S A 105, 786-791.
26. Nylander, I., Vlaskovska, M. & Terenius, L. (1995) The effects of morphine treatment and morphine withdrawal on the dynorphin and enkephalin systems in Sprague-Dawley rats. Psychopharmacology (Berl) 118, 391-400.
27. Purcell, S., Cherny, S.S. & Sham, P.C. (2003) Genetic power calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 19, 149-150.
28. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M.A., Bender, D., Maller, J., Sklar, P., de Bakker, P.I., Daly, M.J. & Sham, P.C. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81, 559-575.
29. Ray, R., Doyle, G.A., Crowley, J.J., Buono, R.J., Oslin, D.W., Patkar, A.A., Mannelli, P., DeMaria, P.A. Jr., O'Brien, C.P. & Berrettini, W.H. (2005) A functional prodynorphin promoter polymorphism and opioid dependence. Psychiatr Genet 15, 295-298.
30. Results from the 2009 National Survey on Drug Use and Health. Volume I. Summary of National Findings. (2010) URL.
31. Rouault, M., Nielsen, D.A., Ho, A., Kreek, M.J. & Yuferov, V. (2011) Cell-specific effects of variants of the 68-base pair tandem repeat on prodynorphin gene promoter activity. Addict Biol 16, 334-346.
32. Sanders, A.R., Levinson, D.F., Duan, J.B., Dennis, J.M., Li, R., Kendler, K.S., Rice, J.P., Shi, J.X., Mowry, B.J., Amin, F., Silverman, J.M., Buccola, N.G., Byerley, W.F., Black, D.W., Freedman, R., Cloninger, C.R. & Gejman, P.V. (2010) The Internet-based MGS2 control sample: self report of mental illness. Am J Psychiatry 167, 854-865.
33. Schwarzer, C. (2009) 30 years of dynorphins - new insights on their functions in neuropsychiatric diseases. Pharmacol Ther 123, 353-370.
34. Shippenberg, T.S. & Herz, A. (1986) Differential effects of mu and kappa opioid systems on motivational processes. NIDA Res Monogr 75, 563-566.
35. Shippenberg, T.S., Zapata, A. & Chefer, V.I. (2007) Dynorphin and the pathophysiology of drug addiction. Pharmacol Ther 116, 306-321.
36. Solecki, W., Ziolkowska, B., Krowka, T., Gieryk, A., Filip, M. & Przewlocki, R. (2009) Alterations of prodynorphin gene expression in the rat mesocorticolimbic system during heroin self-administration. Brain Res 1255, 113-121.
37. Staley, J.K., Rothman, R.B., Rice, K.C., Partilla, J. & Mash, D.C. (1997) Kappa2 opioid receptors in limbic areas of the human brain are upregulated by cocaine in fatal overdose victims. J Neurosci 17, 8225-8233.
38. Steiner, H. & Gerfen, C.R. (1993) Cocaine-induced c-fos messenger RNA is inversely related to dynorphin expression in striatum. J Neurosci 13, 5066-5081.
39. Storey, J.D. (2002) A direct approach to false discovery rates. J R Stat Soc Ser B - Stat Methodol 64, 479-498.
40. Storey, J.D., Taylor, J.E. & Siegmund, D. (2004) Strong control, conservative point estimation and simultaneous conservative consistency of false discovery rates: a unified approach. J R Stat Soc Ser B - Stat Methodol 66, 187-205.
41. Storey, J.D. & Tibshirani, R. (2003) Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 100, 9440-9445.
42. Tsuang, M.T., Lyons, M.J., Meyer, J.M., Doyle, T., Eisen, S.A., Goldberg, J., True, W., Lin, N., Toomey, R. & Eaves, L. (1998) Co-occurrence of abuse of different drugs in men: the role of drug-specific and shared vulnerabilities. Arch Gen Psychiatry 55, 967-972.
43. Walsh, S.L., Strain, E.C., Abreu, M.E. & Bigelow, G.E. (2001) Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology (Berl) 157, 151-162.
44. Wee, S. & Koob, G.F. (2010) The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse. Psychopharmacology (Berl) 210, 121-135.
45. Wei, S.G., Zhu, Y.S., Lai, J.H., Xue, H.X., Chai, Z.Q. & Li, S.B. (2011) Association between heroin dependence and prodynorphin gene polymorphisms. Brain Res Bull 85, 238-242.
46. Williams, T.J., LaForge, K.S., Gordon, D., Bart, G., Kellogg, S., Ott, J. & Kreek, M.J. (2007) Prodynorphin gene promoter repeat associated with cocaine/alcohol codependence. Addict Biol 12, 496-502.
47. Xuei, X., Dick, D., Flury-Wetherill, L., Tian, H.J., Agrawal, A., Bierut, L., Goate, A., Bucholz, K., Schuckit, M., Nurnberger, J. Jr., Tischfield, J., Kuperman, S., Porjesz, B., Begleiter, H., Foroud, T. & Edenberg, H.J. (2006) Association of the kappa-opioid system with alcohol dependence. Mol Psychiatry 11, 1016-1024.
48. Yuferov, V., Ji, F., Nielsen, D.A., Levran, O., Ho, A., Morgello, S., Shi, R., Ott, J. & Kreek, M.J. (2009) A functional haplotype implicated in vulnerability to develop cocaine dependence is associated with reduced PDYN expression in human brain. Neuropsychopharmacology 34, 1185-1197.
49. Zhang, Y., Butelman, E.R., Schlussman, S.D., Ho, A. & Kreek, M.J. (2005) Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors. Psychopharmacology (Berl) 179, 551-558.
50. Zimprich, A., Kraus, J., Woltje, M., Mayer, P., Rauch, E. & Hollt, V. (2000) An allelic variation in the human prodynorphin gene promoter alters stimulus-induced expression. J Neurochem 74, 472-477.